220 related articles for article (PubMed ID: 16400468)
1. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Xiong GS; Wu SM; Zhang XW; Ge ZZ
Braz J Med Biol Res; 2006 Jan; 39(1):85-90. PubMed ID: 16400468
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
[TBL] [Abstract][Full Text] [Related]
3. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
[TBL] [Abstract][Full Text] [Related]
5. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V
N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777
[TBL] [Abstract][Full Text] [Related]
6. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
[TBL] [Abstract][Full Text] [Related]
7. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.
Li ZS; Pan X; Zhang WJ; Gong B; Zhi FC; Guo XG; Li PM; Fan ZN; Sun WS; Shen YZ; Ma SR; Xie WF; Chen MH; Li YQ
Am J Gastroenterol; 2007 Jan; 102(1):46-51. PubMed ID: 17266687
[TBL] [Abstract][Full Text] [Related]
8. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Testoni PA; Mariani A; Masci E; Curioni S
Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060
[TBL] [Abstract][Full Text] [Related]
9. Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.
Guglielmi V; Tutino M; Guerra V; Giorgio P
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5268-5274. PubMed ID: 29228444
[TBL] [Abstract][Full Text] [Related]
10. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.
Yoo JW; Ryu JK; Lee SH; Woo SM; Park JK; Yoon WJ; Lee JK; Lee KH; Hwang JH; Kim YT; Yoon YB
Pancreas; 2008 Nov; 37(4):366-70. PubMed ID: 18953247
[TBL] [Abstract][Full Text] [Related]
11. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
[TBL] [Abstract][Full Text] [Related]
14. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
[TBL] [Abstract][Full Text] [Related]
15. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?
Pezzilli R; Gabbrielli A; Labate AM; D'Alessio P; Barakat B; Costamagna G; Dibenedetti F; Massa M; Merlini G; d'Eril GM
Hepatogastroenterology; 2003; 50(51):851-5. PubMed ID: 12828103
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Rudin D; Kiss A; Wetz RV; Sottile VM
J Gastroenterol Hepatol; 2007 Jul; 22(7):977-83. PubMed ID: 17559376
[TBL] [Abstract][Full Text] [Related]
18. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Watanabe K; Nakamura J; Kikuchi H; Waragai Y; Takasumi M; Hikichi T; Ohira H
World J Gastroenterol; 2018 Jun; 24(22):2392-2399. PubMed ID: 29904246
[TBL] [Abstract][Full Text] [Related]
20. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial.
Wang ZK; Yang YS; Cai FC; Wang YH; Shi XL; Ding C; Li W
Chin Med J (Engl); 2013 Jul; 126(13):2403-8. PubMed ID: 23823808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
